MASH screening study for people with diabetes or obesity
Part of Digestive system, Heart & circulation, Hormones & metabolism clinical trials.
This study screens participants for MASH (a type of liver fat inflammation) using information about your health and risk factors. It may help you and your care team learn whether you could have MASH and need follow-up.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were recently diagnosed with type 2 diabetes, metabolic syndrome, obesity, or high blood pressure, or you already have one of these and you were previously diagnosed
- You meet specific lab or measurement cutoffs for diabetes, obesity, or high blood pressure, OR you meet the study definition of metabolic syndrome
- If you have metabolic syndrome, you must have central obesity (often waist size) plus at least two other risk factors (like triglycerides, HDL, blood pressure, or fasting sugar)
- You do not have hepatitis B, hepatitis C, HIV, or another known liver disease, and you don’t have another condition that could cause liver scarring
- You do not drink more than about 2–3 alcoholic drinks per day (depending on sex), and you can understand the study and sign consent
- You are not pregnant or breastfeeding, and you have not had bariatric (weight loss) surgery in the last 12 months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study screens people with overweight, obesity, or certain metabolic risk factors (like high blood pressure or diabetes) to find early signs of fatty liver disease and other liver problems. The goal is to improve prevention and early treatment through better screening.
This trial tests a new experimental drug called OPK-88006 to see if it can help treat MASH, a serious liver condition linked to excess fat buildup. The study has two parts: one with healthy volunteers to check safety, and one with people who have signs of fatty liver disease.
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
Hear when a new MASLD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.